Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Amazon’s setting up a discounted shop that will fly products to consumers from China. It’s meant to copy Shein and Temu’s business models.
A quarterly survey by the Federal Reserve Bank of Dallas polls around 140 energy firm executives in Texas, Louisiana, and New Mexico.
The Department of Health announced this week that Medicare is cutting prices for dozens of prescription drugs that have outpaced inflation.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
The casual dining industry has been on the brink of destruction for a long time. Now, many in the sector are starting to fall off the edge.
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in.
As the frequency of cyberattacks on healthcare systems and hospitals increases, so too do the costs for preventing them.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
With oil in decline, Masdar, the United Arab Emirates state-backed renewables company, is on an acquisition shopping spree.
Big Tech loves movies, TV shows, and live sports. So why has it shown remarkably little appetite for the TV news business?
You’d think the biggest election year in history would be good news for pollsters. In the case of YouGov, you’d be wrong.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.